PMID- 16646673
OWN - NLM
STAT- MEDLINE
DCOM- 20060710
LR  - 20171116
IS  - 1547-3287 (Print)
IS  - 1547-3287 (Linking)
VI  - 15
IP  - 2
DP  - 2006 Apr
TI  - No polarization of type 1 or type 2 precursor dendritic cells in peripheral blood 
      stem cell collections of non-hodgkin's lymphoma patients mobilized with 
      cyclophosphamide plus G-CSF, GM-CSF, or GM-CSF followed by G-CSF.
PG  - 269-77
AB  - Dendritic cells (DCs) are the most efficient antigen-presenting cells and play a 
      role in immune reconstitution after autologous transplantation. Recent reports 
      suggest that mobilization with granulocyte colony-stimulating factor (G-CSF) 
      containing regimens polarizes DCs into pDC2, which could potentially result with 
      increased Th2 response and decreased graft-versus-host disease (GVHD) in 
      allogeneic transplantation and with decreased cytotoxic Th1 response and graft 
      versus tumor effect, which in autologous transplantation could translate into 
      increased relapse rate. Previously, we have shown that non-Hodgkin's lymphoma 
      (NHL) patients receiving cyclophosphamide (CTX) plus granulocyte- macrophage 
      (GM)-CSF, G-CSF or GM-CSF followed by G-CSF for stem cell collection, mobilize up 
      to five-fold more mature CD80(+) DCs compared to CTX plus G-CSF mobilized 
      patients. Here, we analyzed samples from the same study for the number of pDC1 
      and pDC2 subsets in blood and apheresis products obtained from these patients. 
      Samples from 29 patients were collected. Patients mobilized with CTX plus G-CSF 
      collected a mean of 1.2 +/- 0.4 x 10(6) pDC1/kg per day and 2.2 +/- 1 x 10(6) 
      pDC2/kg per day, whereas patients mobilized with CTX plus GM-CSF collected a mean 
      of 1.1 +/- 0.5 x 10(6) pDC1 and 1.5 +/- 0.9 x 10(6) pDC2/kg per day. Patients 
      mobilized with CTX plus GM-CSF followed by G-CSF collected 2.5 +/- 1.1 x 10(6) 
      pDC1 and 2 +/- 0.5 x 106 pDC2/kg per day, with significantly higher levels of 
      pDC1 +/- pDC2 cells. No significant difference was observed in pDC1/pDC2 ratio 
      between the three mobilization arms. Patients mobilized with the GM-CSFcontaining 
      regimen had a higher probability for survival compared to patients receiving 
      G-CSF alone (median of 55 months vs. 15 months; p = 0.02). These results support 
      the hypothesis that higher levels of DCs in the graft might be associated with 
      prolonged survival of autotransplanted NHL patients. Further similar studies are 
      merited in a larger population of NHL patients.
FAU - Gazitt, Yair
AU  - Gazitt Y
AD  - University of Texas Health Science Center, San Antonio, 78284, USA. 
      gazitt@uthscsa.edu
FAU - Akay, Cagla
AU  - Akay C
FAU - Thomas, Charles 3rd
AU  - Thomas C 3rd
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Stem Cells Dev
JT  - Stem cells and development
JID - 101197107
RN  - 0 (Antigens, CD34)
RN  - 0 (CD11c Antigen)
RN  - 0 (HLA-DR Antigens)
RN  - 0 (IL3RA protein, human)
RN  - 0 (Interleukin-3 Receptor alpha Subunit)
RN  - 0 (Receptors, Interleukin-3)
RN  - 143011-72-7 (Granulocyte Colony-Stimulating Factor)
RN  - 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)
RN  - 8N3DW7272P (Cyclophosphamide)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antigens, CD34/analysis
MH  - Blood Component Removal
MH  - Bone Marrow/drug effects
MH  - CD11c Antigen/analysis
MH  - Cyclophosphamide/*pharmacology
MH  - Dendritic Cells/chemistry/*cytology
MH  - Female
MH  - Granulocyte Colony-Stimulating Factor/administration & dosage/*pharmacology
MH  - Granulocyte-Macrophage Colony-Stimulating Factor/administration & 
      dosage/*pharmacology
MH  - HLA-DR Antigens/analysis
MH  - Hematopoietic Stem Cell Mobilization/*methods
MH  - Hematopoietic Stem Cell Transplantation/methods
MH  - Humans
MH  - Interleukin-3 Receptor alpha Subunit
MH  - Leukocytes/chemistry/cytology
MH  - Lymphoma, Non-Hodgkin/*therapy
MH  - Male
MH  - Middle Aged
MH  - Receptors, Interleukin-3/analysis
MH  - Survival Analysis
MH  - Transplantation, Autologous
EDAT- 2006/05/02 09:00
MHDA- 2006/07/13 09:00
CRDT- 2006/05/02 09:00
PHST- 2006/05/02 09:00 [pubmed]
PHST- 2006/07/13 09:00 [medline]
PHST- 2006/05/02 09:00 [entrez]
AID - 10.1089/scd.2006.15.269 [doi]
PST - ppublish
SO  - Stem Cells Dev. 2006 Apr;15(2):269-77. doi: 10.1089/scd.2006.15.269.